An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

Masami Miki, Ken Kawabe, Hisato Igarashi, Tatsuro Abe, Yoshihiro Ohishi, Risa Hashimoto, Takashi Karashima, Ichiro Yamasaki, Keiji Inoue, Tetsuhide Ito, Yoshihiro Ogawa

Research output: Contribution to journalArticle

Abstract

A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

Original languageEnglish
Pages (from-to)2007-2011
Number of pages5
JournalInternal Medicine
Volume57
Issue number14
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

von Hippel-Lindau Disease
Neuroendocrine Carcinoma
Neuroendocrine Tumors
Neoplasms
Liver
Autopsy
Biopsy
Pancreatic Carcinoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease. / Miki, Masami; Kawabe, Ken; Igarashi, Hisato; Abe, Tatsuro; Ohishi, Yoshihiro; Hashimoto, Risa; Karashima, Takashi; Yamasaki, Ichiro; Inoue, Keiji; Ito, Tetsuhide; Ogawa, Yoshihiro.

In: Internal Medicine, Vol. 57, No. 14, 01.01.2018, p. 2007-2011.

Research output: Contribution to journalArticle

Miki, M, Kawabe, K, Igarashi, H, Abe, T, Ohishi, Y, Hashimoto, R, Karashima, T, Yamasaki, I, Inoue, K, Ito, T & Ogawa, Y 2018, 'An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease', Internal Medicine, vol. 57, no. 14, pp. 2007-2011. https://doi.org/10.2169/internalmedicine.0416-17
Miki, Masami ; Kawabe, Ken ; Igarashi, Hisato ; Abe, Tatsuro ; Ohishi, Yoshihiro ; Hashimoto, Risa ; Karashima, Takashi ; Yamasaki, Ichiro ; Inoue, Keiji ; Ito, Tetsuhide ; Ogawa, Yoshihiro. / An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease. In: Internal Medicine. 2018 ; Vol. 57, No. 14. pp. 2007-2011.
@article{d23fa36bd2404212a2e81feb4b879a70,
title = "An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease",
abstract = "A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40{\%} based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.",
author = "Masami Miki and Ken Kawabe and Hisato Igarashi and Tatsuro Abe and Yoshihiro Ohishi and Risa Hashimoto and Takashi Karashima and Ichiro Yamasaki and Keiji Inoue and Tetsuhide Ito and Yoshihiro Ogawa",
year = "2018",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.0416-17",
language = "English",
volume = "57",
pages = "2007--2011",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "14",

}

TY - JOUR

T1 - An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

AU - Miki, Masami

AU - Kawabe, Ken

AU - Igarashi, Hisato

AU - Abe, Tatsuro

AU - Ohishi, Yoshihiro

AU - Hashimoto, Risa

AU - Karashima, Takashi

AU - Yamasaki, Ichiro

AU - Inoue, Keiji

AU - Ito, Tetsuhide

AU - Ogawa, Yoshihiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

AB - A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

UR - http://www.scopus.com/inward/record.url?scp=85050090288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050090288&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.0416-17

DO - 10.2169/internalmedicine.0416-17

M3 - Article

C2 - 29491307

AN - SCOPUS:85050090288

VL - 57

SP - 2007

EP - 2011

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 14

ER -